The Medical Letter on Drugs and Therapeutics
Maestro Rechargeable System for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the Maestro Rechargeable System (EnteroMedics), a subcutaneously implanted device, for use in adults who have not been able to lose weight with a weight loss program within the past 5 years and who have a body mass index (BMI) of 40 to 45, or a BMI ≥35 and at least one obesity-related comorbidity.

PROCEDURES FOR WEIGHT LOSS — Surgical treatment for obesity is generally limited to patients with a BMI ≥40, or a BMI ≥35 with an obesity-related comorbidity such as diabetes, hypertension, or hypercholesterolemia. Procedures that cause malabsorption (Roux-en-Y gastric bypass and biliopancreatic diversion) result in greater weight loss and more adverse effects than purely restrictive procedures such as adjustable gastric banding or sleeve gastrectomy.1 Gastric balloon devices are inserted endoscopically and can be left in place for up to 6 months; when they ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Maestro Rechargeable System for Weight Loss
Article code: 1493c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian